India's PLI Scheme to Boost GLP-1 Drugs Production

India's PLI Scheme to Boost GLP-1 Drugs Production for Obesity and Diabetes Treatment by 2026

Glucagon-like peptide-1 (GLP-1) drugs are primarily used in the treatment of type 2 diabetes and obesity.

[{"selector":"#anim-976419f0-dc8c-409b-be74-20337c25a3de [data-leaf-element=\"true\"]","keyframes":{"transform":["translate3d(-38.784900826746934%, 0, 0) translate(-25%, 0%) scale(1.5)","translate3d(0%, 0, 0) translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"fill":"forwards"}] [{"selector":"#anim-d67f7871-3d16-4ecb-9a92-a94c6268bf66","keyframes":[{"offset":0,"transform":"translate3d(0, -398.85299%, 0)","easing":"cubic-bezier(.5, 0, 1, 1)"},{"offset":0.29,"transform":"translate3d(0, 0%, 0)","easing":"cubic-bezier(0, 0, .5, 1)"},{"offset":0.45,"transform":"translate3d(0, -112.157460788%, 0)","easing":"cubic-bezier(.5, 0, 1, 1)"},{"offset":0.61,"transform":"translate3d(0, 0%, 0)","easing":"cubic-bezier(0, 0, .5, 1)"},{"offset":0.71,"transform":"translate3d(0, -38.130345844%, 0)","easing":"cubic-bezier(.5, 0, 1, 1)"},{"offset":0.8,"transform":"translate3d(0, 0%, 0)","easing":"cubic-bezier(0, 0, .5, 1)"},{"offset":0.85,"transform":"translate3d(0, -14.318822340999999%, 0)","easing":"cubic-bezier(.5, 0, 1, 1)"},{"offset":0.92,"transform":"translate3d(0, 0%, 0)","easing":"cubic-bezier(0, 0, .5, 1)"},{"offset":0.96,"transform":"translate3d(0, -6.222106643999999%, 0)","easing":"cubic-bezier(.5, 0, 1, 1)"},{"offset":1,"transform":"translate3d(0, 0%, 0)","easing":"cubic-bezier(0, 0, .5, 1)"}],"delay":0,"duration":1500,"fill":"both"}]

This initiative will benefit Indian pharmaceutical giants like Sun Pharma, Cipla, and Lupin, which are already involved in the GLP-1 segment.

[{"selector":"#anim-7fdd1436-0931-4a32-a8d5-d2cdf9ad14f0 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate(-5.173938745765842%, 0%) scale(1.5)","translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] [{"selector":"#anim-60545143-5817-491b-99ad-c7ee3aeecad1","keyframes":{"transform":["translate3d(-117.0418%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":1000,"easing":"cubic-bezier(.2, 0, .8, 1)","fill":"both"}] [{"selector":"#anim-5707e226-91e4-41d2-a482-ddf0cb8a06ef","keyframes":{"transform":["rotateZ(-180deg)","rotateZ(0deg)"]},"delay":0,"duration":1000,"easing":"cubic-bezier(.2, 0, .5, 1)","fill":"forwards"}]

The rising demand for GLP-1 drugs has led to global supply shortages, with companies like Eli Lilly and Novo Nordisk struggling to meet needs

[{"selector":"#anim-4b1faa91-bc5f-45e7-b299-5a53e8d0796e [data-leaf-element=\"true\"]","keyframes":{"transform":["translate(-3.552713678800501e-15%, 0%) scale(1.5)","translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] [{"selector":"#anim-8130bda6-1d79-47ae-b6a2-469db371500e","keyframes":{"opacity":[0,1]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-f03f125a-b47a-414f-b701-88e1bcefeb53","keyframes":{"transform":["scale(0.3333333333333333)","scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}]

[{"selector":"#anim-80fee4ef-fa8c-4b21-b478-6822565ec6c6 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate3d(-28.90624987200394%, 0, 0)","translate3d(0%, 0, 0)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-2763d3f6-c675-4c14-ae54-37524c232207","keyframes":{"transform":["scale(1)","scale(1.5)","scale(0.95)","scale(1)"],"offset":[0,0.33,0.66,1]},"delay":0,"duration":1450,"easing":"ease-in-out","fill":"both","iterations":1}] This presents a golden opportunity for India to expand its pharma capabilities and become a leader in generic drug production. Learn more